A Real World Evidence of Lorlatinib for Taiwanese with advanced ALK Positive Non-Small Cell Lung Cancer

被引：0
|
作者：
Shih, J. -Y. [1 ]
Luo, Y. -H. [2 ]
Chang, G. -C. [3 ]
Chang, J. W. -C. [4 ]
Wang, C. -C. [5 ]
Yang, T. [6 ]
Fang, W. [7 ]
Shau, W. -Y. [7 ]
机构：
[1] Natl Taiwan Univ Hosp, Taipei, Taiwan
[2] Taipei Vet Gen Hosp, Taipei, Taiwan
[3] Chung Shang Med Univ Hosp, Taichung, Taiwan
[4] Chang Gung Memory Hosp Linko, Taoyuan, Taiwan
[5] Chang Gung Mem Hosp Kaohsiung, Kaohsiung, Taiwan
[6] Taichung Vet Gen Hosp, Taichung, Taiwan
[7] Pfizer, Taipei, Taiwan
来源：
JOURNAL OF THORACIC ONCOLOGY | 2022年 / 17卷 / 09期
关键词：
real world; lorlatinib; lung cancer;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
EP08.02-15
引用
收藏
页码：S475 / S475
页数：1
相关论文
共 50 条
  • [1] Real-world evidence of lorlatinib therapy in Taiwanese patients with advanced anaplastic lymphoma kinase-positive non-small cell lung cancer
    Shih, Jin-Yuan
    Luo, Yung-Hung
    Chang, Gee-Chen
    Chang, John Wen-Cheng
    Wang, Chin-Chou
    Yang, Tsung-Ying
    Fang, Wei-Tse
    Shau, Wen-Yi
    JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION, 2024, 123 (08) : 875 - 881
  • [2] Real-world efficacy and safety of lorlatinib in treating advanced ALK-positive non-small cell lung cancer patients
    Lee, Po-Hsin
    Chen, Kun-Chieh
    Hsu, Kuo-Hsuan
    Huang, Yen-Hsiang
    Tseng, Jeng-Sen
    Yang, Tsung-Ying
    Chang, Gee-Chen
    ANTI-CANCER DRUGS, 2021, 32 (10) : 1099 - 1104
  • [3] Lorlatinib for the treatment of ALK-positive metastatic non-small cell lung cancer
    Choo, Joan Rou-En
    Soo, Ross A.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2020, 20 (04) : 233 - 240
  • [4] Real-world Analysis of the Efficacy and Safety of lorlatinib in Patients with ALK-Positive Non-small Cell Lung Cancer in Korea
    不详
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S402 - S402
  • [5] Long term efficacy and safety of Lorlatinib in ALK-positive non-small cell lung cancer: A case report
    Qian, Jialin
    Chu, Tianqing
    CURRENT PROBLEMS IN CANCER: CASE REPORTS, 2025, 17
  • [6] Impact of lorlatinib on patient-reported outcomes in patients with advanced ALK-positive or ROS1-positive non-small cell lung cancer
    Peters, Solange
    Shaw, Alice T.
    Besse, Benjamin
    Felip, Enriqueta
    Solomon, Benjamin J.
    Soo, Ross A.
    Bearz, Alessandra
    Gadgeel, Shirish M.
    Lin, Chia-Chi
    Kao, Steven
    Seto, Takashi
    Masters, Elizabeth T.
    Abbattista, Antonello
    Clancy, Jill S.
    Thurm, Holger
    Reisman, Arlene
    Peltz, Gerson
    Camidge, D. Ross
    LUNG CANCER, 2020, 144 : 10 - 19
  • [7] Real-world outcomes in patients with ALK-positive non-small cell lung cancer treated with crizotinib
    Davis, K. L.
    Kaye, J. A.
    Masters, E. T.
    Iyer, S.
    CURRENT ONCOLOGY, 2018, 25 (01) : E40 - E49
  • [8] Crizotinib: A targeted therapy in advanced ALK-positive non-small cell lung cancer
    Toffart, A. -C.
    Sakhri, L.
    Moro-Sibilot, D.
    REVUE DE PNEUMOLOGIE CLINIQUE, 2013, 69 (02) : 111 - 116
  • [9] Brigatinib for the treatment of ALK-positive advanced non-small cell lung cancer patients
    Passaro, A.
    Prelaj, A.
    Pochesci, A.
    Spitaleri, G.
    Rossi, G.
    Del Signore, E.
    Catania, C.
    de Marinis, F.
    DRUGS OF TODAY, 2017, 53 (08) : 435 - 446
  • [10] LORLATINIB ALK/ROS1 inhibitor Treatment of non-small cell lung cancer
    Gajdosik, Z.
    DRUGS OF THE FUTURE, 2016, 41 (12) : 715 - 723
12345